ADVB
Advanced Biomed·NASDAQ
--
--(--)
--
--(--)
ADVB fundamentals
During Q2 2026, Advanced Biomed (ADVB) reported revenue of --, a YoY change of 0.00%. Net income was 6.86M, a YoY change of 855.36%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | Q1,2026 | Q2,2026 | TTM |
|---|
Start Date | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | -- |
Revenue | 0 -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | 0 -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 2.70M -- | 408.62K -- | 853.21K -- | 790.23K -- | 1.02M -62.26% | 440.25K +7.74% | 651.30K -23.66% | 745.41K -5.67% | 704.61K -30.86% | 520.03K +18.12% | 280.06K -57.00% | 762.74K +2.32% | 1.21M +72.09% | 523.91K +0.75% | 396.64K +41.63% | 2.90M -- |
Selling, General and Administrative Expenses | 508.23K -- | 292.01K -- | 282.97K -- | 582.06K -- | 531.00K +4.48% | 271.06K -7.18% | 462.92K +63.59% | 431.90K -25.80% | 495.50K -6.68% | 338.32K +24.82% | 67.67K -85.38% | 512.28K +18.61% | 978.32K +97.44% | 287.92K -14.90% | 210.31K +210.80% | 1.99M -- |
General and Administrative Expenses | 754.84K -- | -- -- | 282.97K -- | -574.99K -- | 1.69M +123.63% | 271.06K -- | 462.92K +63.59% | 431.90K +175.12% | 495.50K -70.65% | 338.32K +24.82% | 67.67K -85.38% | 512.28K +18.61% | 978.32K +97.44% | 287.92K -14.90% | 210.31K +210.80% | 1.99M -- |
Research and Development Expenses | 574.29K -- | 116.61K -- | 570.23K -- | 208.17K -- | 488.17K -15.00% | 169.19K +45.09% | 188.39K -66.96% | 313.51K +50.60% | 209.11K -57.16% | 181.70K +7.40% | 212.40K +12.75% | 250.46K -20.11% | 234.22K +12.01% | 235.99K +29.88% | 186.33K -12.27% | 907.01K -- |
Loss on Impairment of Other Assets | 1.62M -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Income | -2.70M -- | -408.62K -- | -853.21K -- | -790.23K -- | -1.02M +62.26% | -440.25K -7.74% | -651.30K +23.66% | -745.41K +5.67% | -704.61K +30.86% | -520.03K -18.12% | -280.06K +57.00% | -762.74K -2.32% | -1.21M -72.09% | -523.91K -0.75% | -396.64K -41.63% | -2.90M -- |
Non-Operating Income (Loss) | 1.62K -- | -740.10K -- | 467.82K -- | 272.13K -- | -661.41K -40877.25% | -331.07K +55.27% | 505.96K +8.15% | -310.82K -214.22% | -104.77K +84.16% | 254.45K +176.86% | -299.43K -159.18% | -621.13K -99.84% | 510.93K +587.65% | 137.01K -46.15% | 7.40M +2570.97% | 7.43M -- |
Gain (Loss) on Foreign Currency Exchange | -- -- | -- -- | -- -- | -- -- | -511.64K -- | -331.69K -- | 486.71K -- | -284.99K -- | -164.72K +67.81% | 252.10K +176.00% | -314.81K -164.68% | -621.98K -118.24% | 501.56K +404.50% | 136.26K -45.95% | 42.94K +113.64% | 58.79K -- |
Other Non-Operating Income (Loss) | 1.68K -- | -740.54K -- | 467.60K -- | 272.67K -- | -171.05K -10281.49% | 604 +100.08% | -719 -100.15% | -25.93K -109.51% | 26.53K +115.51% | 2.34K +287.58% | 0 +100.00% | 841 +103.24% | -145 -100.55% | 303 -87.06% | 7.35M -- | 7.35M -- |
Net Interest Expense | 58 -- | -443 -- | -224 -- | 545 -- | -21.28K -36789.66% | -14 +96.84% | -19.97K -8813.39% | -104 -119.08% | -33.41K -57.01% | -10 +28.57% | -15.38K +22.98% | 0 +100.00% | -9.51K +71.53% | -448 -4380.00% | -9.21K +40.13% | -19.17K -- |
Interest Income | -58 -- | 443 -- | 224 -- | -545 -- | 21.28K +36789.66% | 14 -96.84% | 19.97K +8813.39% | 104 +119.08% | 33.41K +57.01% | 10 -28.57% | 15.38K -22.98% | 0 -100.00% | 9.51K -71.53% | 448 +4380.00% | 9.21K -40.13% | 19.17K -- |
Pretax Income From Continuing Operations | -2.70M -- | -1.15M -- | -385.39K -- | -518.11K -- | -1.68M +37.73% | -771.32K +32.85% | -145.34K +62.29% | -1.06M -103.86% | -809.39K +51.84% | -265.58K +65.57% | -579.49K -298.70% | -1.38M -31.02% | -701.61K +13.32% | -386.90K -45.68% | 7.00M +1308.33% | 4.53M -- |
Income Tax Expense | 0 -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- |
Income from Discontinued Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -328.41K -- | -- -- | -- -- | -- -- | -144.26K +56.07% | -- -- |
Net Income | -2.70M -- | -1.15M -- | -385.39K -- | -518.11K -- | -1.68M +37.73% | -771.32K +32.85% | -145.34K +62.29% | -1.06M -103.86% | -809.39K +51.84% | -265.58K +65.57% | -907.90K -524.65% | -1.38M -31.02% | -701.61K +13.32% | -386.90K -45.68% | 6.86M +855.36% | 4.39M -- |
Net Income Attributable to Owners of the Company | -2.70M -- | -1.15M -- | -385.39K -- | -518.11K -- | -1.68M +37.73% | -771.32K +32.85% | -145.34K +62.29% | -1.06M -103.86% | -809.39K +51.84% | -265.58K +65.57% | -907.90K -524.65% | -1.38M -31.02% | -701.61K +13.32% | -386.90K -45.68% | 6.86M +855.36% | 4.39M -- |
Net Income Attributable to Common Stockholders | -2.70M -- | -1.15M -- | -385.39K -- | -518.11K -- | -1.68M +37.73% | -771.32K +32.85% | -145.34K +62.29% | -1.06M -103.86% | -809.39K +51.84% | -265.58K +65.57% | -907.90K -524.65% | -1.38M -31.02% | -701.61K +13.32% | -386.90K -45.68% | 6.86M +855.36% | 4.39M -- |
Other Comprehensive Income | 204.28K -- | 354.39K -- | -222.54K -- | -186.10K -- | 589.41K +188.53% | 270.87K -23.57% | -462.96K -108.04% | 361.59K +294.30% | 149.82K -74.58% | -303.85K -212.17% | 433.11K +193.55% | 39.70K -89.02% | 49.39K -67.03% | -86.54K +71.52% | -380.40K -187.83% | -377.85K -- |
Total Comprehensive Income | -2.49M -- | -794.33K -- | -607.92K -- | -704.21K -- | -1.09M +56.26% | -500.44K +37.00% | -608.30K -0.06% | -694.64K +1.36% | -659.57K +39.55% | -569.43K -13.78% | -474.80K +21.95% | -1.34M -93.51% | -652.22K +1.11% | -473.44K +16.86% | 6.48M +1464.27% | 4.01M -- |
Total Comprehensive Income Attributable to Owners of the Company | -2.49M -- | -794.33K -- | -607.92K -- | -704.21K -- | -1.09M +56.26% | -500.44K +37.00% | -608.30K -0.06% | -694.64K +1.36% | -659.57K +39.55% | -569.43K -13.78% | -474.80K +21.95% | -1.34M -93.51% | -652.22K +1.11% | -473.44K +16.86% | 6.48M +1464.27% | 4.01M -- |
Basic EPS | -- -- | -0.05 -- | 0 -- | -- -- | -- -- | -0.04 +20.00% | -0.01 -- | -0.05 -- | -- -- | -0.01 +75.00% | -0.05 -400.00% | -0.07 -40.00% | -0.03 -- | -0.02 -100.00% | 0.31 +720.00% | 0.19 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | 0 -- | -- -- | -- -- | -0.04 -- | -0.01 -- | -0.05 -- | -- -- | -0.01 +75.00% | -0.03 -200.00% | -0.07 -40.00% | -- -- | -0.02 -100.00% | 0.32 +1166.67% | -- -- |
Basic EPS from Discontinued Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.02 -- | -- -- | -- -- | -- -- | -0.01 +50.00% | -- -- |
Diluted EPS | -- -- | -0.05 -- | 0 -- | -- -- | -- -- | -0.04 +20.00% | -0.01 -- | -0.05 -- | -- -- | -0.01 +75.00% | -0.05 -400.00% | -0.07 -40.00% | -- -- | -0.02 -100.00% | 0.31 +720.00% | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | 0 -- | -- -- | -- -- | -0.04 -- | -0.01 -- | -0.05 -- | -- -- | -0.01 +75.00% | -0.03 -200.00% | -0.07 -40.00% | -- -- | -0.02 -100.00% | 0.32 +1166.67% | -- -- |
Diluted EPS from Discontinued Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.02 -- | -- -- | -- -- | -- -- | -0.01 +50.00% | -- -- |
You can ask Aime
What factors drove the changes in Advanced Biomed's revenue and profit?What is Advanced Biomed's latest dividend and current dividend yield?Did Advanced Biomed beat or miss consensus estimates last quarter?What is the revenue and EPS growth rate for Advanced Biomed year over year?What were the key takeaways from Advanced Biomed’s earnings call?What is Advanced Biomed's gross profit margin?What does Advanced Biomed do and what are its main business segments?What is the market's earnings forecast for Advanced Biomed next quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
